HENRY EMERLE: Open Payments
NPI 1336450790 · DAVENPORT, IA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,197 in 24 payments from 9 companies in 2025. Trend: 2023 $51 · 2024 $562 · 2025 $2,197
Consulting: $1,840Food & beverage: $357
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 12 | $1,948 |
| Otsuka America Pharmaceutical, Inc. | 3 | $67 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $50 |
| Teva Pharmaceuticals USA, Inc. | 2 | $40 |
| ABBVIE INC. | 1 | $28 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Lundbeck LLC | 1 | $19 |
| Almatica Pharma LLC | 1 | $18 |
| Corium, LLC | 1 | $9 |
Products named: COBENFY, CAPLYTA, UZEDY, REXULTI, VRAYLAR, ABILIFY ASIMTUFII, ABILIFY MAINTENA, Auvelity.
Industry payments across IA — which companies pay providers there.
